Northern Trust Corp Has $4.79 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Northern Trust Corp lifted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 36.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 643,157 shares of the company’s stock after acquiring an additional 171,374 shares during the quarter. Northern Trust Corp owned approximately 0.94% of EyePoint Pharmaceuticals worth $4,792,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of EYPT. Barclays PLC raised its position in EyePoint Pharmaceuticals by 410.4% in the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after purchasing an additional 197,033 shares during the last quarter. Cyndeo Wealth Partners LLC increased its stake in shares of EyePoint Pharmaceuticals by 35.5% in the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company’s stock valued at $127,000 after buying an additional 4,450 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of EyePoint Pharmaceuticals by 40.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock valued at $108,000 after buying an additional 4,179 shares in the last quarter. abrdn plc bought a new position in shares of EyePoint Pharmaceuticals in the fourth quarter valued at about $1,719,000. Finally, Deltec Asset Management LLC bought a new position in shares of EyePoint Pharmaceuticals in the fourth quarter valued at about $151,000. 99.41% of the stock is currently owned by institutional investors.

EyePoint Pharmaceuticals Trading Down 5.5%

EyePoint Pharmaceuticals stock opened at $5.87 on Thursday. The company has a market cap of $403.92 million, a PE ratio of -2.94 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $13.99. The company’s 50-day moving average is $5.86 and its two-hundred day moving average is $7.24.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $24.50 million during the quarter, compared to the consensus estimate of $8.84 million. Research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on EYPT shares. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Mizuho reduced their target price on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, May 16th. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Finally, Chardan Capital dropped their price objective on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.38.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.